within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M09A_OtherDrugsForDisordersOfTheMusculoSkeletalSystem.M09AX11_Palovarotene;

model Palovarotene
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.33,
    Cl = 3.7777777777777777e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.282,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.004166666666666667,
    Tlag = 19.8,
    Vdp = 0.49,
    k12 = 1.352777777777778e-05,
    k21 = 1.352777777777778e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Palovarotene</td></tr><tr><td>ATC code:</td><td>M09AX11</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>282</td><td>L</td></tr>
    <tr><td>clearance:</td><td>13.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Palovarotene is a selective retinoic acid receptor gamma (RARγ) agonist developed for the treatment of fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder involving heterotopic ossification. As of 2023, palovarotene is approved in some regions for FOP and used under clinical investigation in others.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration of single and multiple doses.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M09AX11 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Palovarotene;
